Real Life Study in Myopic Neovascularization — VIC

Myopic Choroidal Neovascularisation Clinical Trial

Official title:
Real Life Study in Myopic Neovascularization

Status Active, not recruiting

Clinical Trial Summary

This is a multi centre, single arm, prospective observational phase 4 study in naive or pretreated patients with myopic neovascularization. The patients will be treated with intravitreal injections of Aflibercept following a real life protocol. This sudy aims to evaluate the visual acuity during a 36 months period of time.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03797547
Study type	Observational
Source	Poitiers University Hospital
Contact
Status	Active, not recruiting
Phase
Start date	June 22, 2018
Completion date	January 30, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05677685` - VISUPRIME® Eye Drops	N/A
Completed	`NCT03971162` - Intravitreal Conbercept Injection in Patients With Myopic Choroidal Neovascularization	N/A
Recruiting	`NCT05494775` - Effect of Corona Virus on Intravitreal Injections	N/A
Suspended	`NCT04222842` - CM082 in Patients With Myopic Choroidal Neovascularization (CNV)	Phase 1
Not yet recruiting	`NCT06357559` - OCTA Changes in Choroidal Neovascularization in High Myopia